List of Tables
Table 1. Global HER2 Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global HER2 Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global HER2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global HER2 Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global HER2 Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global HER2 Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global HER2 Inhibitors Sales by Region (2020-2025) & (K Units)
Table 8. Global HER2 Inhibitors Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global HER2 Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global HER2 Inhibitors Sales Share by Manufacturers (2020-2025)
Table 12. Global HER2 Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global HER2 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global HER2 Inhibitors by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HER2 Inhibitors as of 2024)
Table 16. Global HER2 Inhibitors Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global HER2 Inhibitors Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers HER2 Inhibitors Manufacturing Base and Headquarters
Table 19. Global HER2 Inhibitors Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global HER2 Inhibitors Sales by Type (2020-2025) & (K Units)
Table 23. Global HER2 Inhibitors Sales by Type (2026-2031) & (K Units)
Table 24. Global HER2 Inhibitors Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global HER2 Inhibitors Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global HER2 Inhibitors ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global HER2 Inhibitors Sales by Application (2020-2025) & (K Units)
Table 29. Global HER2 Inhibitors Sales by Application (2026-2031) & (K Units)
Table 30. HER2 Inhibitors High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global HER2 Inhibitors Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global HER2 Inhibitors Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global HER2 Inhibitors ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America HER2 Inhibitors Growth Accelerators and Market Barriers
Table 37. North America HER2 Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America HER2 Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe HER2 Inhibitors Growth Accelerators and Market Barriers
Table 40. Europe HER2 Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe HER2 Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific HER2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific HER2 Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific HER2 Inhibitors Growth Accelerators and Market Barriers
Table 45. Southeast Asia HER2 Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America HER2 Inhibitors Investment Opportunities and Key Challenges
Table 47. Central and South America HER2 Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa HER2 Inhibitors Investment Opportunities and Key Challenges
Table 49. Middle East and Africa HER2 Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Biocon Corporation Information
Table 51. Biocon Description and Major Businesses
Table 52. Biocon Product Models, Descriptions and Specifications
Table 53. Biocon Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Biocon Sales Value Proportion by Product in 2024
Table 55. Biocon Sales Value Proportion by Application in 2024
Table 56. Biocon Sales Value Proportion by Geographic Area in 2024
Table 57. Biocon HER2 Inhibitors SWOT Analysis
Table 58. Biocon Recent Developments
Table 59. Roche Corporation Information
Table 60. Roche Description and Major Businesses
Table 61. Roche Product Models, Descriptions and Specifications
Table 62. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Roche Sales Value Proportion by Product in 2024
Table 64. Roche Sales Value Proportion by Application in 2024
Table 65. Roche Sales Value Proportion by Geographic Area in 2024
Table 66. Roche HER2 Inhibitors SWOT Analysis
Table 67. Roche Recent Developments
Table 68. AbbVie Corporation Information
Table 69. AbbVie Description and Major Businesses
Table 70. AbbVie Product Models, Descriptions and Specifications
Table 71. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. AbbVie Sales Value Proportion by Product in 2024
Table 73. AbbVie Sales Value Proportion by Application in 2024
Table 74. AbbVie Sales Value Proportion by Geographic Area in 2024
Table 75. AbbVie HER2 Inhibitors SWOT Analysis
Table 76. AbbVie Recent Developments
Table 77. Merck Sharp & Dohme Corporation Information
Table 78. Merck Sharp & Dohme Description and Major Businesses
Table 79. Merck Sharp & Dohme Product Models, Descriptions and Specifications
Table 80. Merck Sharp & Dohme Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Merck Sharp & Dohme Sales Value Proportion by Product in 2024
Table 82. Merck Sharp & Dohme Sales Value Proportion by Application in 2024
Table 83. Merck Sharp & Dohme Sales Value Proportion by Geographic Area in 2024
Table 84. Merck Sharp & Dohme HER2 Inhibitors SWOT Analysis
Table 85. Merck Sharp & Dohme Recent Developments
Table 86. Novartis Corporation Information
Table 87. Novartis Description and Major Businesses
Table 88. Novartis Product Models, Descriptions and Specifications
Table 89. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Novartis Sales Value Proportion by Product in 2024
Table 91. Novartis Sales Value Proportion by Application in 2024
Table 92. Novartis Sales Value Proportion by Geographic Area in 2024
Table 93. Novartis HER2 Inhibitors SWOT Analysis
Table 94. Novartis Recent Developments
Table 95. Mylan Corporation Information
Table 96. Mylan Description and Major Businesses
Table 97. Mylan Product Models, Descriptions and Specifications
Table 98. Mylan Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Mylan Recent Developments
Table 100. Puma Biotechnology Corporation Information
Table 101. Puma Biotechnology Description and Major Businesses
Table 102. Puma Biotechnology Product Models, Descriptions and Specifications
Table 103. Puma Biotechnology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Puma Biotechnology Recent Developments
Table 105. Pfizer Corporation Information
Table 106. Pfizer Description and Major Businesses
Table 107. Pfizer Product Models, Descriptions and Specifications
Table 108. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Pfizer Recent Developments
Table 110. Boehringer Ingelheim Corporation Information
Table 111. Boehringer Ingelheim Description and Major Businesses
Table 112. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 113. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Boehringer Ingelheim Recent Developments
Table 115. Johnson & Johnson Corporation Information
Table 116. Johnson & Johnson Description and Major Businesses
Table 117. Johnson & Johnson Product Models, Descriptions and Specifications
Table 118. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Johnson & Johnson Recent Developments
Table 120. Genentech Corporation Information
Table 121. Genentech Description and Major Businesses
Table 122. Genentech Product Models, Descriptions and Specifications
Table 123. Genentech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Genentech Recent Developments
Table 125. GlaxoSmithKline Corporation Information
Table 126. GlaxoSmithKline Description and Major Businesses
Table 127. GlaxoSmithKline Product Models, Descriptions and Specifications
Table 128. GlaxoSmithKline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. GlaxoSmithKline Recent Developments
Table 130. Key Raw Materials Distribution
Table 131. Raw Materials Key Suppliers
Table 132. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 133. Milestones in Production Technology Evolution
Table 134. Distributors List
Table 135. Market Trends and Market Evolution
Table 136. Market Drivers and Opportunities
Table 137. Market Challenges, Risks, and Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. HER2 Inhibitors Product Picture
Figure 2. Global HER2 Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Monotherapy Product Picture
Figure 4. Combination Therapy Product Picture
Figure 5. Global HER2 Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Stomach Cancer
Figure 7. Adenocarcinoma
Figure 8. Cellular Cancer
Figure 9. Other
Figure 10. HER2 Inhibitors Report Years Considered
Figure 11. Global HER2 Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 13. Global HER2 Inhibitors Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global HER2 Inhibitors Revenue Market Share by Region (2020-2031)
Figure 15. Global HER2 Inhibitors Sales (2020-2031) & (K Units)
Figure 16. Global HER2 Inhibitors Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global HER2 Inhibitors Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers HER2 Inhibitors Sales Volume Market Share in 2024
Figure 19. Global HER2 Inhibitors Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Monotherapy Revenue Market Share by Manufacturer in 2024
Figure 22. Combination Therapy Revenue Market Share by Manufacturer in 2024
Figure 23. Global HER2 Inhibitors Sales Market Share by Type (2020-2031)
Figure 24. Global HER2 Inhibitors Revenue Market Share by Type (2020-2031)
Figure 25. Global HER2 Inhibitors Sales Market Share by Application (2020-2031)
Figure 26. Global HER2 Inhibitors Revenue Market Share by Application (2020-2031)
Figure 27. North America HER2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 28. North America HER2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 29. North America Top 5 Manufacturers HER2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 30. North America HER2 Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 31. North America HER2 Inhibitors Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 32. North America HER2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 33. North America HER2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 34. US HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 35. Canada HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 36. Mexico HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 37. Europe HER2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 38. Europe HER2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Europe Top 5 Manufacturers HER2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 40. Europe HER2 Inhibitors Sales Volume (K Units) by Type (2020-2031)
Figure 41. Europe HER2 Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 42. Europe HER2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 43. Europe HER2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 44. Germany HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 45. France HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 46. U.K. HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 47. Italy HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 48. Russia HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 49. Asia-Pacific HER2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 50. Asia-Pacific HER2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Top 8 Manufacturers HER2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 52. Asia-Pacific HER2 Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 53. Asia-Pacific HER2 Inhibitors Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 54. Asia-Pacific HER2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 55. Asia-Pacific HER2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 56. Indonesia HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 57. Japan HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 58. South Korea HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 59. China Taiwan HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 60. India HER2 Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 61. Central and South America HER2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 62. Central and South America HER2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Central and South America Top 5 Manufacturers HER2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 64. Central and South America HER2 Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 65. Central and South America HER2 Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 66. Central and South America HER2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 67. Central and South America HER2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 68. Brazil HER2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 69. Argentina HER2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 70. Middle East, and Africa HER2 Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 71. Middle East and Africa HER2 Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 72. Middle East and Africa Top 5 Manufacturers HER2 Inhibitors Sales Revenue (US$ Million) in 2024
Figure 73. Middle East and Africa HER2 Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 74. South America HER2 Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 75. Middle East and Africa HER2 Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 76. Middle East and Africa HER2 Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 77. GCC Countries HER2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 78. Turkey HER2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 79. Egypt HER2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 80. South Africa HER2 Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 81. HER2 Inhibitors Industry Chain Mapping
Figure 82. Regional HER2 Inhibitors Manufacturing Base Distribution (%)
Figure 83. Global HER2 Inhibitors Production Market Share by Region (2020-2031)
Figure 84. HER2 Inhibitors Production Process
Figure 85. Regional HER2 Inhibitors Production Cost Structure
Figure 86. Channels of Distribution (Direct Vs Distribution)
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
